|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.220 USD | +9.90% |
|
+6.22% | +23.33% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +395.5% | 2 | |||||
| 1,218.72 | +10.94% | 29 | ||||||
| 252.87 | +10.72% | 23 | ||||||
| 253.55 | +17.12% | 29 | ||||||
| 358.83 | +12.21% | 18 | ||||||
| 221.03 | +26.26% | 21 | ||||||
| 154.88 | +5.72% | 21 | ||||||
| 314.41 | +7.33% | 24 | ||||||
| 352.77 | +4.49% | 30 | ||||||
| 157.57 | +27.32% | 28 | ||||||
| 29.19 | +15.78% | 27 | ||||||
| 548.69 | +21.49% | 29 | ||||||
| 63.08 | +16.81% | 25 | ||||||
| 96.7 | +30.43% | 23 | ||||||
| 20.77 | +7.85% | 19 | ||||||
| 9,973.33 | +32.1% | 15 | ||||||
| 6,086.87 | +23.37% | 15 | ||||||
| 81.14 | +67.57% | 16 | ||||||
| 49.5 | +30.81% | 19 | ||||||
| 4.148 | +24.2% | 17 | ||||||
| Average | 1,012.45 | +39.40% | 22 | ||||||
| Weighted average by Cap. | 714.61 | +14.96% | 25 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
